UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE

UTOPIA aims to carry out Seed and Series A operations in the Life Sciences sector, an industry with significant investment opportunities. In Italy, it is still relatively underrepresented and characterized by a gap in terms of VC investments compared to the leading countries of the European Union.

More Info

OUR FOCUS

  • DISEASE MODIFYING DRUGS
  • CROSS BORDER CON ARTIFICIAL INTELLIGENCE
  • MEDICAL DEVICES
  • DIAGNOSTIC TOOLS AND BIOMARKERS
More Info

OUR INVESTMENTS

  • Novavido Srl
  • PerFormS Srl 
  • Lighthouse Biotech Srl 
  • Drug Discovery and Clinic Srl
  • CaSRevolution Srl
  • T-One Therapeutics Srl
More Info

The promoting members

UTOPIA SIS S.p.A.

UTOPIA SOCIETA’ DI INVESTIMENTO SEMPLICE aims to carry out Seed and Series A operations in the Life Sciences sector, an industry with significant investment opportunities. In Italy, it is still relatively underrepresented and characterized by a gap in terms of VC investments compared to the leading countries of the European Union.
More Info

What is a SIS

SOCIETA’ DI INVESTIMENTO SEMPLICE (SIS) is a Venture Capital vehicle aimed at investing in start-ups and unlisted SMEs and subject to a subsidized regime.

 

More Info

Our Focus

I

DISEASE MODIFYING DRUGS

I

CROSS BORDER CON ARTIFICIAL INTELLIGENCE

I

MEDICAL DEVICES

I

DIAGNOSTIC TOOLS AND BIOMARKERS

More Info

Our portfolio

Scopri di più
Scopri di più
Scopri di più
Scopri di più
Scopri di più
Scopri di più

Latest News

Utopia SIS invests 2.5 million euros in T One Therapeutics

Utopia SIS invests 2.5 million euros in T One Therapeutics

Sep 21, 2022

Spin of INGM, the National Institute of Molecular Genetics “Romeo and Enrica Invernizzi”, dedicated to the development of new anti-tumor immunotherapies based on the blockade of epigenetic signals that regulate the dominant immunosuppression in tumor tissues. Bologna,...

Utopia SIS invests in PerFormS

Utopia SIS invests in PerFormS

Mar 21, 2022

PerFormS Srl is a spin-off of the University of Modena and Reggio Emilia, accompanied in its development in recent years by the G-Factor incubator of Fondazione Golinelli in Bologna. The investment will be covered by the guarantee of the Medio Credito Centrale for 80%...

Utopia SIS and Pariter Partners invest in Lighthouse Biotech

Utopia SIS and Pariter Partners invest in Lighthouse Biotech

Dec 21, 2021

Lighthouse Biotech aims to define new boundaries for oncology research through new liquid biopsy technologies The investment will be the first to be guaranteed by Medio Credito Centrale for over 80% Milan, December 29, 2021 - Utopia SIS, an investment company...